Effect of the SARS-CoV-2 pandemic on metabolic control in patients with type 2 diabetes: a 5-year cohort follow-up managed by a dynamic multidisciplinary team in Northeastern Mexico
Open Access
- 25 April 2024
- journal article
- research article
- Published by Springer Nature in Diabetology & Metabolic Syndrome
- Vol. 16 (1) , 1-14
Abstract
The SARS-CoV-2 pandemic brought a radical shift in the healthcare system and suboptimal care for vulnerable patients, such as those with Type 2 Diabetes Mellitus (T2D). Therefore, we compared metabolic control and macro/microvascular complications of patients with T2D before and throughout the three-year SARS-CoV-2 pandemic. A retrospective observational cohort of subjects with T2D studied from 2018 to 2022 in Northern Mexico was treated by a dynamic multidisciplinary team. Levels of Glycated hemoglobin (HbA1c), fasting serum glucose (FG), LDL-Cholesterol (LDL-C), blood pressure (BP), albuminuria, triglycerides, Body Mass Index (BMI), and FIB-4 score, micro and macrovascular complications were evaluated. A total of 999 patients were studied, 51.7% males with a mean (SD) age of 60.1 (12.7) years. Adequate glycemic control based on HbA1c increased by 15.2% and 42.3% in FSG (p < 0.001) between the beginning 2018 and the end of 2022. LDL-C control decreased by 5.1% between 2018 and 2022 (p < 0.001). Systolic BP control decreased by 2.6% (p < 0.001), whereas diastolic BP control increased by 1.8% (p = 0.01) between 2018 and 2022. Albuminuria control increased by 8.5% (p = 0.002). When comparing the Area Under the Curve (AUC) of metabolic parameters between patients who developed SARS-CoV-2 vs. those who did not, AUC was statistically higher in those who developed SARS-CoV-2 (p < 0.05). Diabetic neuropathy was the most prevalent microvascular complication (n = 35; 3.6%); ischemic heart disease was the most frequent macrovascular complication (n = 11;1.1%). A multidisciplinary dynamic team that adapts to the pandemic SARS-CoV-2 maintains and increases metabolic control in subjects with type 2 diabetes in Mexico. This represents a low percentage of chronic complications. The AUC of metabolic parameters of subjects with SARS-CoV-2 infection is higher, reflecting more variability in metabolic control.Keywords
This publication has 43 references indexed in Scilit:
- Metabolic alterations upon SARS-CoV-2 infection and potential therapeutic targets against coronavirus infectionSignal Transduction and Targeted Therapy, 2023
- The impact of COVID-19 on diet quality, food security and nutrition in low and middle income countries: A systematic review of the evidenceClinical Nutrition, 2021
- Trends in Diabetes Treatment and Control in U.S. Adults, 1999–2018New England Journal of Medicine, 2021
- Obesity in COVID-19 era, implications for mechanisms, comorbidities, and prognosis: a review and meta-analysisInternational Journal of Obesity, 2021
- SARS–CoV-2 Receptor ACE2 Gene Is Associated with Hypertension and Severity of COVID 19: Interaction with Sex, Obesity, and SmokingAmerican Journal of Hypertension, 2021
- SGLT-2 inhibitors for COVID-19 — A miracle waiting to happen or just another beat around the bush?Primary Care Diabetes, 2020
- Sex differences in metabolic regulation and diabetes susceptibilityDiabetologia, 2019
- Effect of diabetes duration and glycaemic control on 14-year cause-specific mortality in Mexican adults: a blood-based prospective cohort studyThe Lancet Diabetes & Endocrinology, 2018
- Trend over time in hepatic fibrosis score in a cohort of type 2 diabetes patientsDiabetes Research and Clinical Practice, 2018
- Redesigning Diabetes Care: Defining the Role of Endocrinologists Among Alternative ProvidersCurrent Diabetes Reports, 2016